AbbVie seeks Rinvoq alopecia approval after second Phase III success
If approved, Rinvoq could be set to dominate the alopecia market after exhibiting better efficacy than competitor Olumiant.
22 August 2025
22 August 2025
If approved, Rinvoq could be set to dominate the alopecia market after exhibiting better efficacy than competitor Olumiant.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.